RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Emergent BioSolutions Stock

Emergent BioSolutions Employees 2024

Emergent BioSolutions Employees

1,834

Ticker

EBS

ISIN

US29089Q1058

WKN

A0LC2W

In 2024, Emergent BioSolutions employed 1,834 people, a 0% change from the 1,834 number of employees in the previous year.

Emergent BioSolutions Aktienanalyse

What does Emergent BioSolutions do?

Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Emergent BioSolutions's Employee Base

Emergent BioSolutions's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Emergent BioSolutions's operational capacity and future potential.

Year-to-Year Comparison

Assessing Emergent BioSolutions's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Emergent BioSolutions's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Emergent BioSolutions’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Emergent BioSolutions stock

How many employees does Emergent BioSolutions have this year?

Emergent BioSolutions has 1,834 undefined employees this year.

How many employees did Emergent BioSolutions have compared to the previous year?

Compared to the previous year, Emergent BioSolutions had 0% more employees.

What impact did the number of employees have on the company Emergent BioSolutions?

The number of employees has a direct impact on the efficiency and productivity of Emergent BioSolutions. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Emergent BioSolutions?

The number of employees can also have an impact on investors of Emergent BioSolutions, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Emergent BioSolutions affect the company?

An increase in equity of Emergent BioSolutions can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Emergent BioSolutions's equity affect the company?

A reduction in equity of Emergent BioSolutions can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Emergent BioSolutions?

Some factors that can influence the equity of Emergent BioSolutions include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Emergent BioSolutions so important for investors?

The equity of Emergent BioSolutions is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Emergent BioSolutions influence the company?

The number of employees at Emergent BioSolutions can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Emergent BioSolutions evolved in recent years?

In recent years, the number of employees at Emergent BioSolutions has changed by 0.

How many employees does Emergent BioSolutions currently have?

Emergent BioSolutions currently has 1,834 undefined employees.

Why is the number of employees important for investors of Emergent BioSolutions?

The number of employees is important for investors of Emergent BioSolutions as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Emergent BioSolutions take to change the number of employees?

To change the number of employees, Emergent BioSolutions can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Emergent BioSolutions pay?

Over the past 12 months, Emergent BioSolutions paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emergent BioSolutions is expected to pay a dividend of 0 USD.

What is the dividend yield of Emergent BioSolutions?

The current dividend yield of Emergent BioSolutions is .

When does Emergent BioSolutions pay dividends?

Emergent BioSolutions pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emergent BioSolutions?

Emergent BioSolutions paid dividends every year for the past 0 years.

What is the dividend of Emergent BioSolutions?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emergent BioSolutions located?

Emergent BioSolutions is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emergent BioSolutions kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emergent BioSolutions from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Emergent BioSolutions pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Emergent BioSolutions in the year 2023?

In the year 2023, Emergent BioSolutions distributed 0 USD as dividends.

In which currency does Emergent BioSolutions pay out the dividend?

The dividends of Emergent BioSolutions are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Emergent BioSolutions stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Emergent BioSolutions

Our stock analysis for Emergent BioSolutions Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emergent BioSolutions Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.